The “2022 Chinese Expert Consensus on Risk Assessment and Management of Panvascular Disease in Patients with T2DM” recommends metformin alone, or in combination with GLP1 receptor agonists or SGLT2 inhibitors, as a first-line hypoglycemic agent in the absence of explicit contraindications [110]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.